IRTC

Company Overview — What Does iRhythm Technologies, Inc. Do?

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California. iRhythm Technologies, Inc. (IRTC) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Quentin S. Blackford and employs approximately 1,790 people, headquartered in San Francisco, California. With a market capitalization of $3.8B, IRTC is one of the notable companies in the Healthcare sector.

iRhythm Technologies, Inc. (IRTC) Stock Rating — Reduce (April 2026)

As of April 2026, iRhythm Technologies, Inc. receives a Reduce rating with a composite score of 38.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IRTC ranks #3,475 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, iRhythm Technologies, Inc. ranks #540 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IRTC Stock Price and 52-Week Range

iRhythm Technologies, Inc. (IRTC) currently trades at $115.24. The stock lost $2.92 (2.5%) in the most recent trading session. The 52-week high for IRTC is $212.00, which means the stock is currently trading -45.6% from its annual peak. The 52-week low is $92.52, putting the stock 24.6% above its annual trough. Recent trading volume was 305K shares, suggesting relatively thin trading activity.

Is IRTC Overvalued or Undervalued? — Valuation Analysis

iRhythm Technologies, Inc. (IRTC) carries a value factor score of 34/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 25.10x, versus the sector average of 2.75x. The price-to-sales ratio is 5.59x, compared to 1.66x for the average Healthcare stock.

At current multiples, iRhythm Technologies, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

iRhythm Technologies, Inc. Profitability — ROE, Margins, and Quality Score

iRhythm Technologies, Inc. (IRTC) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -63.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -9.4% versus the sector average of -33.1%.

On a margin basis, iRhythm Technologies, Inc. reports gross margins of 70.0%, compared to 71.5% for the sector. The operating margin is -17.3% (sector: -66.1%). Net profit margin stands at -15.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 30.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IRTC Debt, Balance Sheet, and Financial Health

iRhythm Technologies, Inc. has a debt-to-equity ratio of 568.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 4.63x, indicating strong short-term liquidity. Total debt on the balance sheet is $649M. Cash and equivalents stand at $256M.

IRTC has a beta of 0.79, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for iRhythm Technologies, Inc. is 60/100, reflecting average volatility within the normal range for its sector.

iRhythm Technologies, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, iRhythm Technologies, Inc. reported revenue of $686M and earnings per share (EPS) of $-1.39. Net income for the quarter was $-96M. Gross margin was 70.0%. Operating income came in at $-110M.

In FY 2025, iRhythm Technologies, Inc. reported revenue of $747M and earnings per share (EPS) of $-1.39. Net income for the quarter was $-45M. Gross margin was 70.6%. Revenue grew 26.2% year-over-year compared to FY 2024. Operating income came in at $-57M.

In Q3 2025, iRhythm Technologies, Inc. reported revenue of $193M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-5M. Gross margin was 71.1%. Revenue grew 30.7% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, iRhythm Technologies, Inc. reported revenue of $187M and earnings per share (EPS) of $-0.44. Net income for the quarter was $-14M. Gross margin was 71.2%. Revenue grew 26.1% year-over-year compared to Q2 2024. Operating income came in at $-19M.

Over the past 8 quarters, iRhythm Technologies, Inc. has demonstrated a growth trajectory, with revenue expanding from $148M to $686M. Investors analyzing IRTC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IRTC Dividend Yield and Income Analysis

iRhythm Technologies, Inc. (IRTC) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IRTC Momentum and Technical Analysis Profile

iRhythm Technologies, Inc. (IRTC) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

IRTC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, iRhythm Technologies, Inc. (IRTC) ranks #540 out of 838 stocks based on the Blank Capital composite score. This places IRTC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IRTC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IRTC vs S&P 500 (SPY) comparison to assess how iRhythm Technologies, Inc. stacks up against the broader market across all factor dimensions.

IRTC Next Earnings Date

No upcoming earnings date has been announced for iRhythm Technologies, Inc. (IRTC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IRTC? — Investment Thesis Summary

The quantitative profile for iRhythm Technologies, Inc. suggests caution. The quality score of 29/100 flags below-average profitability. The value score of 34/100 indicates premium valuation. Momentum is weak at 39/100, a headwind for near-term performance. Low volatility (stability score 60/100) reduces downside risk.

In summary, iRhythm Technologies, Inc. (IRTC) earns a Reduce rating with a composite score of 38.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IRTC stock.

Related Resources for IRTC Investors

Explore more research and tools: IRTC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IRTC head-to-head with peers: IRTC vs AZN, IRTC vs SLGL, IRTC vs VMD.